CG Oncology initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of CG Oncology with an Overweight rating and $75 price target. CG’s oncolytic virus cretostimogene has shown compelling monotherapy data for treatment of Non-Muscle-Invasive Bladder Cancer, an indication with a very high unmet need that’s been amplified by a shortage of the standard of care, the analyst tells investors in a research note. Strong interim results have already been reported, and final data are expected around year-end 2024, supporting a Biologics License Application filing in the second half of 2025.